Skip to main content

Table 1 Clinical and pathological data of the patients enrolled in the study

From: Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma

 

Number of cases (%)

Radiosensitive

Radioresistant

X2 (p value)

n (%)

n (%)

Gender

 Male

30 (88.2)

12 (40.0)

18 (60.0)

1.0

 Female

4 (11.8)

2 (50.0)

2 (50.0)

Age

 ≤60 years

16 (47.1)

5 (31.2)

11 (68.8)

0.51

 >60 years

18 (52.9)

9 (50.0)

9 (50.0)

Tobacco consumption

 Yes

31 (91.2)

14 (45.2)

17 (54.8)

0.25

 No

3 (8.8)

0 (0)

3 (100.0)

Tumor site

 Supraglottic

7 (20.6)

2 (28.6)

5 (71.4)

1.0

 Glottic

27 (79.4)

12 (44.4)

15 (55.6)

Tumor stage

 I

16 (47.1)

8 (50)

8 (50)

0.49

 II

18 (52.9)

6 (33.3)

12 (66.7)

Radiotherapy dose

 <70 Gy

10 (29.4)

5 (50.0)

5 (50.0)

0.7

 ≥70 Gy

24 (70.6)

9 (37.5)

15 (62.5)

Treatment time

 ≤55 days

20 (58.8)

9 (45.0)

11 (55.0)

0.72

 >55 days

14 (41.2)

5 (37.5)

9 (64.3)